Biogen has announced its intention to acquire RayThera in a deal valued at up to $1 billion.

Biogen has announced the acquisition of RayThera in a deal that could be worth up to $1 billion. This strategic move expands Biogen's portfolio and capabilities within the biotechnology sector.

Accenture's shares dropped by 13% after the company announced $4.18 billion in cybersecurity deals, including acquiring majority stakes in cybersecurity firms. The decline was attributed to a weaker-than-expected revenue outlook for the fourth quarter.